in metastatic colorectal versus standard approved KRAS exon 2 cancer. Oncologist 2015; testing was inconsequential when 20:14-8. compared with the amount of money saved by not treating the additional 18% of patients who harbor additional RAS mutations (beyond exon 2) with therapy. 9 Study of Sakai K, Tsurutani J, A study into the clinical utility of 2015 diagnostic Yamanaka T, et al: multiplex deep sequencing to detect accuracy Extended RAS and BRAF somatic mutations in KRAS, NRAS and Mutation Analysis Using BRAF in colorectal cancer [100 clinical Next-Generation formalin-fixed paraffin embedded (FFPE) Sequencing. PLoS ONE tumour specimens, 15 plasma samples]. 10:e0121891, 2015 The genetic screening assay using a sequencer was validated for the detection of clinically relevant RAS and BRAF mutations using FFPE and liquid samples. 10. Clinical Kruglyak KM, Lin E, Ong Review of NGS technology in the 2016 review FS. Next-Generation diagnosis and treatment of lung cancer, Sequencing and providing a high-level overview of the Applications to the role of NGS in precision oncology and the Diagnosis and Treatment technical challenges involved. of Lung Cancer. Adv Exp Med Biol. 11. Clinical Sepulveda AR, Hamilton Clinical practice guidelines 2017 guidelines SR, Allegra CJ, et al: recommending molecular biomarkers for Molecular Biomarkers for best practice in the diagnosis and the Evaluation of treatment of colorectal cancer. These Colorectal Cancer: guidelines highlight the importance of Guideline From the concurrent knowledge of the RAS and American Society for BRAF status of mCRC. Clinical Pathology, College of American Pathologists, Association for Molecular
in metastatic colorectal cancer. Oncologist 2015; 20:14-8. versus standard approved KRAS exon 2 testing was inconsequential when compared with the amount of money saved by not treating the additional 18% of patients who harbor additional RAS mutations (beyond exon 2) with therapy. 9 Study of diagnostic accuracy Sakai K, Tsurutani J, Yamanaka T, et al: Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PLoS ONE 10:e0121891, 2015 A study into the clinical utility of multiplex deep sequencing to detect somatic mutations in KRAS, NRAS and BRAF in colorectal cancer [100 clinical formalin-fixed paraffin embedded (FFPE) tumour specimens, 15 plasma samples]. The genetic screening assay using a sequencer was validated for the detection of clinically relevant RAS and BRAF mutations using FFPE and liquid samples. 2015 10. Clinical review Kruglyak KM, Lin E, Ong FS. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer. Adv Exp Med Biol. Review of NGS technology in the diagnosis and treatment of lung cancer, providing a high-level overview of the role of NGS in precision oncology and the technical challenges involved. 2016 11. Clinical guidelines Sepulveda AR, Hamilton SR, Allegra CJ, et al: Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Clinical practice guidelines recommending molecular biomarkers for best practice in the diagnosis and treatment of colorectal cancer. These guidelines highlight the importance of concurrent knowledge of the RAS and BRAF status of mCRC. 2017
Application-to-MSAC-RCPA-SomaticTumourGenePanel-Version%202.4(revised).docx